Long-term outcomes of severe rheumatic mitral stenosis after undergoing percutaneous mitral commissurotomy and mitral valve replacement: A 10-year experience
Journal of Cardiovascular and Thoracic Research · 30.06.2022 · 14 (2) · 101-107
DOI: 10.34172/jcvtr.2022.16 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Cardiovascular and Thoracic Research, online erschienen am 12.06.2022. Verfasst von Wasinee Promratpan und 3 weiteren Autor:innen. Beteiligte Einrichtung: Division of Cardiovascular Medicine, Department of Medicine, Faculty of Medicine, Chulalongkorn University, Cardiac Center, King Chulalongkorn Memori…. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 20 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Introduction
Percutaneous mitral commissurotomy (PTMC) and mitral valve replacement (MVR) are treatments of choice for severe rheumatic mitral stenosis (MS). Data regarding the long-term outcomes of patients who underwent PTMC and MVR are limited.
Methods
A retrospective cohort study was conducted to evaluate the long-term outcomes of patients with severe rheumatic MS who underwent PTMC or MVR between 2010 to 2020. The primary outcome comprised of all-cause death, stroke or systemic embolism, heart failure hospitalization and re-intervention. Cox regression was used to investigate predictors of the primary outcome.
Results
264 patients were included in analysis, 164 patients (62.1%) in PTMC group and 100 patients in MVR group (37.9%). The majority were females (80.7%) and had atrial fibrillation (68.6%). The mean age was 49.52 (SD: 13.03) years old. MVR group had more age and AF, higher Wilkins’ score with smaller MVA. Primary outcome occurred significantly higher in PTMC group (37.2% vs 22%, P=0.002), as well as, re-intervention (18.3% vs 0%, P 50 mmHg (HR 2.99; 95%CI 1.01, 8.84; P=0.047) were the only predictors of primary outcome.
Conclusion
Primary outcome occurred in PTMC group more than MVR group which was driven by re-intervention. However, all-cause mortality, stroke or systemic embolism and heart failure hospitalization were not significantly different.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Division of Cardiovascular Medicine, Department of Medicine, Faculty of Medicine, Chulalongkorn University, Cardiac Center, King Chulalongkorn Memorial Hospital, 10330, Bangkok, Thailand.
ORCID-Profile: Wasinee Promratpan, Nonthikorn Theerasuwipakorn, Vorarit Lertsuwunseri
Zitieren
APA
Promratpan, W., Theerasuwipakorn, N., Lertsuwunseri, V., & Srimahachota, S. (2022). Long-term outcomes of severe rheumatic mitral stenosis after undergoing percutaneous mitral commissurotomy and mitral valve replacement: A 10-year experience. Journal of Cardiovascular and Thoracic Research, 14(2), 101-107. https://doi.org/10.34172/jcvtr.2022.16
Vancouver
Promratpan W, Theerasuwipakorn N, Lertsuwunseri V, Srimahachota S. Long-term outcomes of severe rheumatic mitral stenosis after undergoing percutaneous mitral commissurotomy and mitral valve replacement: A 10-year experience. Journal of Cardiovascular and Thoracic Research. 2022;14(2):101-107. doi:10.34172/jcvtr.2022.16
BibTeX
@article{Promratpan2022,
author = {Promratpan, Wasinee and Theerasuwipakorn, Nonthikorn and Lertsuwunseri, Vorarit and Srimahachota, Suphot},
title = {Long-term outcomes of severe rheumatic mitral stenosis after undergoing percutaneous mitral commissurotomy and mitral valve replacement: A 10-year experience},
journal = {Journal of Cardiovascular and Thoracic Research},
year = {2022},
volume = {14},
number = {2},
pages = {101--107},
doi = {10.34172/jcvtr.2022.16}
}
EUVIMED